This round was led by Jeito Capital and Forbion Growth, with participation from Seroba, Pictet Group and other existing investors Forbion Ventures, Schroders Capital and BioGeneration Ventures (BGV).
The deal team consisted of Annefleur van Oel, Twan Hamers and Sofie Hertsenberg (Corporate M&A). The team further consisted of Marloes van der Laan, Eline Keuning (Corporate notarial), Pedro Paraguay (Tax), Victorine Dijkstra, Jurriaan Bos (Competition)
About Azafaros
Azafaros is a clinical-stage biopharmaceutical company dedicated to the development of disease-modifying therapies for rare lysosomal storage disorders. The proceeds from this financing will support the advancement of its lead asset, nizubaglustat, which is expected to enter Phase 3 clinical trials for Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses later this year. The funding will enable Azafaros to further expand its development pipeline into additional indications.
